Literature DB >> 8232812

Changes in the cerebrovascular effects of endothelin-1 and nicardipine after experimental subarachnoid hemorrhage.

J A Alabadí1, J B Salom, G Torregrosa, F J Miranda, T Jover, E Alborch.   

Abstract

The role of endothelium-related factors in the pathogenesis of cerebral vasospasm after subarachnoid hemorrhage (SAH) has gained interest since the discovery of endothelin-1 (ET-1). We have examined, before and after SAH, the responsiveness of the cerebrovascular bed of the goat to ET-1, the sources of Ca2+ in ET-1-induced responses, and the ability of the Ca2+ entry blocker nicardipine to counteract them. Before SAH, injection of ET-1 into the cerebral circulation increased cerebrovascular resistance, thereby producing dose-dependent reductions in cerebral blood flow (CBF), which were prevented by nicardipine. In isolated middle cerebral arteries, ET-1 induced concentration-dependent contractions, which were equally inhibited in Ca(2+)-free medium (without or with ethylene glycol tetraacetic acid) and by the Ca2+ entry blocker nicardipine. On the third day after SAH, CBF was reduced by 28% and cerebrovascular resistance increased by 39%. At the same time, both ET-1-induced reductions in CBF and the constricting effects of ET-1 in vitro were enhanced. The ability of nicardipine to increase CBF and to inhibit the effects of ET-1 was impaired as a result of reduced dependence of cerebral arteries on extracellular Ca2+. On the seventh day after SAH, CBF and cerebrovascular resistance returned to control values, and effects of ET-1 became normal. It is suggested that the hyperreactivity to ET-1 of the cerebrovascular bed induced by SAH could have a role in the development of vasospasm, which could reduce the vascular effects of Ca2+ entry blockers after SAH.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8232812     DOI: 10.1227/00006123-199310000-00022

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  4 in total

Review 1.  Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought.

Authors:  Ryszard M Pluta; Jacob Hansen-Schwartz; Jens Dreier; Peter Vajkoczy; R Loch Macdonald; Shigeru Nishizawa; Hideotoshi Kasuya; George Wellman; Emanuela Keller; Alois Zauner; Nicholas Dorsch; Joseph Clark; Shigeki Ono; Talat Kiris; Peter Leroux; John H Zhang
Journal:  Neurol Res       Date:  2009-03       Impact factor: 2.448

2.  Safety and feasibility of intra-arterial nicardipine for the treatment of subarachnoid hemorrhage-associated vasospasm: initial clinical experience with high-dose infusions.

Authors:  J G Tejada; R A Taylor; M S Ugurel; M Hayakawa; S K Lee; J C Chaloupka
Journal:  AJNR Am J Neuroradiol       Date:  2007-05       Impact factor: 3.825

3.  Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm.

Authors:  Neeraj Badjatia; Mehmet A Topcuoglu; Johnny C Pryor; James D Rabinov; Christopher S Ogilvy; Bob S Carter; Guy A Rordorf
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

4.  Cilostazol prevents endothelin-induced smooth muscle constriction and proliferation.

Authors:  Yoshifumi Kawanabe; Maki Takahashi; Xingjian Jin; Shakila Abdul-Majeed; Andromeda M Nauli; Youssef Sari; Surya M Nauli
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.